Latest Pharma and Biotech News
Pharmaceutical
2 December 2024 GLP-1 receptor (GLP-1R) products have gained immense popularity in recent years, and four are currently approved in major markets to treat obesity—all of which are injectables.
Today's issue
Refine Search
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Adaptimmune Therapeutics reported promising data Wednesday from its pivotal Phase II trial of lete-cel in certain solid tumors with few effective treatments. 14 November 2024
Biotechnology
Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, has entered into a strategic discovery collaboration with Swiss pharma giant Roche. 14 November 2024
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which pleased investors. 14 November 2024
Biotechnology
Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important developments along with its third-quarter 2024 financials, reporting a $0.54 per share loss. 13 November 2024
Pharmaceutical
Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, safety and tolerability of twice-yearly lenacapavir for HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. 13 November 2024
Pharmaceutical
US biotech major Amgen closed 7% lower on Tuesday after investors questioned whether reductions in bone mineral density might be linked to the use of its investigational obesity candidate MariTide (maridebart cafraglutide, formerly AMG 133) in a Phase I trial. 13 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting impressive Phase IIa data this week, but also of its in-silico drug discovery model and the wider artificial intelligence (AI) field. 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Biotechnology
Dutch firm Argenx and China’s Zai Lab have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa). 13 November 2024
Biotechnology
Sanofi has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma. 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Pharmaceutical
Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered into a research collaboration and license agreement with Novartis. 13 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Danish biopharma company Lundbeck posted a robust 18% revenue increase in the third quarter of 2024, reaching 5.7 billion Danish kroner ($815 million). Earnings per share rose to 0.78 kroner, marking a 15% year-on-year improvement, while adjusted earnings per share increased by 11%. 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
All news
Biotechnology
Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. 3 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche subsidiary Genentech for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. 3 December 2024
Biotechnology
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. 3 December 2024
Pharmaceutical
Suzhou’s Atom Therapeutics, has inked a deal with China Medical System (CMS) to commercialize lingdolinurad (ABP-671) in China, Hong Kong, and Macao. 3 December 2024
Biotechnology
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
Biotechnology
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeier as its chief business officer (CBO). 3 December 2024
Biotechnology
Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European biopharmaceutical companies reporting a 325% surge ($921 million) from 2023 to 2024 year-to-date (YTD), compared to a 90.5% rise ($256 million) in the USA. 3 December 2024
Biotechnology
China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate (fruquintinib) and Tyvyt (sintilimab). 3 December 2024
Pharmaceutical
The Advanced Research Projects Agency for Health (ARPA-H), an agency established in 2022 in the USA, has launched a new Advancing Clinical Trial Readiness (ACTR) initiative. 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Biotechnology
New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for patients severely impacted by migraine. 3 December 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics announced that it has strengthened the company’s leadership and executive team with two new appointments. 3 December 2024
Pharmaceutical
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
Biotechnology
French biotech Ipsen has entered an exclusive global licensing agreement with Biomunex Pharmaceuticals to develop BMX-502, a first-in-class T cell engager. 3 December 2024
Pharmaceutical
Swedish pharma Orexo and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for the former firm to commercialize the digital mental health program for depression, Deprexis, in the USA. 2 December 2024
Biotechnology
Netherlands and USA-based Merus has inked an exclusive licensing accord with privately-held Partner Therapeutics (PTx), for the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the USA. 2 December 2024
Pharmaceutical
Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III PANOVA-3 trial, demonstrating a statistically-significant improvement in median overall survival (mOS) versus control. 2 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze